Source-grounded facts extracted from Xencor Inc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Xencor Inc shareholders approved Advisory Vote on the Compensation of the Company’s Named Executive Officers at the 2026-06-16 meeting.
“The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of its named executive officers as disclosed in the Proxy Statement.”
Xencor Inc shareholders approved Approval of the Amendment and Restatement of the Xencor, Inc. 2023 Equity Incentive Plan to Increase the Number of Authorized Shares Available for Issuance thereunder by 4,000,000 Shares at the 2026-06-16 meeting.
“The Company’s stockholders approved the amendment and restatement of the Xencor, Inc. 2023 Equity Incentive Plan to increase the number of authorized shares reserved for issuance thereunder by 4,000,000 shares.”
Xencor Inc shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-16 meeting.
“The Company’s stockholders ratified the selection by the Audit Committee of the Board of Directors of KPMG LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Xencor Inc shareholders approved Election of Directors at the 2026-06-16 meeting.
“The Company’s stockholders elected the nine persons listed below as directors, each to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified.”
Xencor Inc reported the first quarter ended March 31, 2026 results: revenue $4.5 million. Guidance reaffirmed.
“debt securities totaled $541.8 million as of March 31, 2026, compared to $610.8 million as of December 31, 2025. Revenue for the first quarter ended March 31, 2026 was $4.5 million, compared to $32.7 million for the same period in 2025. Revenue earned in the first quarter of 2026 was primarily non-cash royalty revenue from Incyte and Alexion, compared to”
Xencor Inc terminated Amended and Restated Collaboration and License Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd (effective 2026-09-04).
“On March 4, 2026, Xencor, Inc. (the “Company”) received a notice of termination of an Amended and Restated Collaboration and License Agreement (the “Agreement”), effective as of June 1, 2024, with Genentech, Inc. (“GNE”) and F. Hoffmann-La Roche Ltd (“Roche” and, GNE and Roche, collectively, “Genentech”), pursuant to which Genentech has elected to terminate the Agreement in its entirety for convenience. The effective date of the termination of the Agreement is September 4, 2026.”
Nancy Valente resigned as Executive Vice President and Chief Development Officer at Xencor Inc.
“On May 5, 2025, Nancy Valente, Executive Vice President and Chief Development Officer, notified the Company of her intention to resign from the Company effective June 6, 2025, and remain as a senior advisor.”
Xencor Inc reported that prior financial statements should not be relied upon.
“of the proceeds from the sale of future royalties as part of our non-routine transactions, and (ii) a deficiency in the design of controls related to the evaluation of certain tax legislation, which together led to the restatement of the Company’s audited financial statements for the year ended December 31, 2023 and the unaudited financial statements for the quarterly periods ended March 31, 2024, June 30, 2024 and September 30, 2024.”
Xencor Inc engaged KPMG LLP as its auditor.
“On February 27, 2025, the Audit Committee approved the appointment of KPMG LLP (“KPMG”) as the Company’s new independent registered public accounting firm, effective as of March 3, 2025.”
Xencor Inc dismissed RSM US LLP as its auditor.
“On February 27, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors of the Company, dismissed RSM US LLP (“RSM”) as the Company’s independent registered public accounting firm, effective immediately.”
Todd Simpson was appointed as Director at Xencor Inc.
“Todd Simpson was appointed to serve as a new member of the Board of Directors (the “Board”) of Xencor, Inc. (the “Company”).”
Xencor Inc reported that prior financial statements should not be relied upon.
“of the proceeds from the sale of future royalties as part of our non-routine transactions, and (ii) a deficiency in the design of controls related to the evaluation of certain tax legislation, which together led to the restatement of the Company’s audited financial statements for the year ended December 31, 2023 and the unaudited financial statements for the quarterly periods ended March 31, 2024, June 30, 2024 and September 30, 2024.”
Xencor Inc engaged KPMG LLP as its auditor.
“On February 27, 2025, the Audit Committee approved the appointment of KPMG LLP (“KPMG”) as the Company’s new independent registered public accounting firm, effective as of March 3, 2025.”
Xencor Inc dismissed RSM US LLP as its auditor.
“On February 27, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors of Xencor, Inc., a Delaware corporation (the “Company”), dismissed RSM US LLP (“RSM”) as the Company’s independent registered public accounting firm, effective immediately.”
Xencor Inc reported that prior financial statements should not be relied upon.
“On February 11, 2025, the Audit Committee of the Board of Directors (the “Audit Committee”) of Xencor, Inc. (the “Company”), after consultation with the Company’s management and RSM US LLP, the Company’s independent registered public accounting firm (“RSM”) concluded that the following financial statements should no longer be relied upon because of errors in such financial statements”
Dagmar Rosa-Bjorkeson departed as Director at Xencor Inc.
“On September 30, 2024 Dagmar Rosa-Bjorkeson provided notice to the board of directors (the “Board”) of Xencor, Inc. (the “Company”) of her intent not to stand for reelection to the Board at the Company’s 2025 Annual Meeting of Stockholders.”
Xencor Inc reported the first quarter ended March 31, 2024 results: revenue $12.8 million, net income $68.0 million, or $(1.11) on a fully diluted per share basis, EPS $(1.11) on a fully diluted per share basis.
“marketable debt securities totaled $646.7 million as of March 31, 2024, compared to $697.4 million on December 31, 2023. Revenues for the first quarter ended March 31, 2024 were $12.8 million, compared to $19.0 million for the same period in 2023. Total revenues earned in the first quarter of 2024 included non-cash royalty revenue from Xencor’s Alexion and”
Bart Cornelissen was appointed as Senior Vice President and Chief Financial Officer at Xencor Inc.
“on April 9, 2024 (the “Start Date”), Mr. Bart Cornelissen, age 46, was appointed as Senior Vice President and Chief Financial Officer of the Company for an indefinite term.”
John Kuch retired as Senior Vice President and Chief Financial Officer at Xencor Inc.
“Effective on April 9, 2024, Mr. Kuch will step down from his role as Chief Financial Officer of the Company.”
Xencor Inc reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
“On February 27, 2024, Xencor, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2023 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.”
Xencor Inc entered into Royalty Conversion arrangement under the New Collaboration Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd valued at tiered royalties on a product-by-product and country-by-country basis ranging from low double-digit (effective 2024-06-01).
“Pursuant to the Royalty Conversion, in connection with any program under the Original Collaboration Agreement, including XmAb306 (RO7310729), the Company will be entitled to receive tiered royalties on a product-by-product and country-by-country basis ranging from low double-digit to mid-teens percentages.”
Xencor Inc entered into Amended and Restated Collaboration and License Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd valued at $600 million in milestones; tiered royalties from low double-digit to mid-teens percentages (effective 2024-06-01).
“On November 14, 2023, the Company entered into an Amended and Restated Collaboration and License Agreement (the “New Collaboration Agreement”) with Genentech, Inc., a Delaware corporation, having its principal place of business at 1 DNA Way, South San Francisco, California 94080 (“GNE”), and F. Hoffmann-La Roche Ltd, a corporation organized and existing under the laws of Switzerland, having its principal place of business at Grenzacherstrasse 124, CH 4070 Basel, Switzerland (“Roche”) (GNE and Roche, collectively, “Genentech”).”
Xencor Inc reported financial results for the third quarter ended September 30, 2023.
“On November 7, 2023, Xencor, Inc. announced its financial results for the third quarter ended September 30, 2023 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.”
Xencor Inc entered into Monjuvi Agreement with OCM Life Sciences Portfolio LP valued at upfront payment of $22.5 million (effective 2023-11-03).
“(the “Company”) and OCM Life Sciences Portfolio LP, an investment vehicle of OMERS, one of Canada’s largest defined benefit pension plans (“OMERS”) entered into a royalty purchase agreement (the “Ultomiris Agreement”).”
Xencor Inc entered into Ultomiris Agreement with OCM Life Sciences Portfolio LP valued at upfront payment of $192.5 million (effective 2023-11-03).
“On November 3, 2023, Xencor, Inc. (the “Company”) and OCM Life Sciences Portfolio LP, an investment vehicle of OMERS, one of Canada’s largest defined benefit pension plans (“OMERS”) entered into a royalty purchase agreement (the “Ultomiris Agreement”).”
John Kuch departed as Senior Vice President and Chief Financial Officer at Xencor Inc.
“On October 24, 2023, John Kuch, Senior Vice President and Chief Financial Officer, notified Xencor, Inc. (the “Company”) of his intention to retire from the Company effective March 31, 2024.”
Barbara Klencke was appointed as Director at Xencor Inc.
“On September 15, 2023, the Board of Directors of the Company (the “Board”) was increased from seven to eight board members and Barbara Klencke, M.D., was appointed to serve as a new member of the Board.”
Xencor Inc reported second quarter ended June 30, 2023 results: revenue $45.5 million.
“Total revenue for the second quarter ended June 30, 2023 was $45.5 million”
Allen Yang departed as other_named_officer at Xencor Inc.
“On April 26, 2023, Xencor, Inc. (the “Company”), announced that Dr. Allen Yang was stepping down from his role as an executive officer of the Company, effective as of May 1, 2023.”
Xencor Inc shareholders approved Advisory Vote on the Frequency of Future Non-Binding Advisory Stockholder Votes on the Compensation of the Company’s Named Executive Officers at the 2023-06-14 meeting.
“Proposal 5. Advisory Vote on the Frequency of Future Non-Binding Advisory Stockholder Votes on the Compensation of the Company’s Named Executive Officers The Company’s stockholders approved, on an advisory (non-binding) basis, "one year" for the frequency of future advisory stockholder votes on the compensation of its named executive officers. The final voting results are as follows: Broker One Year Two Year Three Year Abstentions Non-Votes 53,884,063 124 1,778,570 7,562 2,680,975”
Xencor Inc shareholders approved Approval of the Company’s 2023 Equity Incentive Plan at the 2023-06-14 meeting.
“Proposal 4. Approval of the Company’s 2023 Equity Incentive Plan The Company’s stockholders approved the Company’s 2023 Equity Incentive Plan. The final voting results are as follows: Broker Votes for Votes Against Abstentions Non-Votes 45,680,668 9,952,360 37,292 2,680,975”
Xencor Inc shareholders approved Advisory Vote on the Compensation of the Company’s Named Executive Officers at the 2023-06-14 meeting.
“Proposal 3. Advisory Vote on the Compensation of the Company’s Named Executive Officers The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of its named executive officers as disclosed in the Proxy Statement. The final voting results are as follows: Broker Votes for Votes Against Abstentions Non-Votes 53,903,252 1,760,454 6,613 2,680,975”
Xencor Inc shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-06-14 meeting.
“Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Board of Directors of RSM US LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2023. The final voting results are as follows: Broker Votes for Votes Against Abstentions Non-Votes 57,762,046 582,716 6,532 -”
Xencor Inc shareholders approved Election of seven directors at the 2023-06-14 meeting.
“Proposal 1. Election of Directors The Company’s stockholders elected the seven persons listed below as directors, each to serve until the 2024 Annual Meeting of Stockholders and until their successors are duly elected and qualified. The final voting results are as follows: Votes Broker Votes for Withheld Non-Votes Dr. Bassil I. Dahiyat 54,034,880 1,635,439 2,680,975 Dr. Ellen G. Feigal 53,709,086 1,961,233 2,680,975 Dr. Kevin C. Gorman 54,022,790 1,647,529 2,680,975 Mr. Kurt A. Gustafson 53,917,267 1,753,052 2,680,975 Dr. A. Bruce Montgomery 53,973,899 1,696,420 2,680,975 Mr. Richard J. Ranieri 53,792,814 1,877,505 2,680,975 Ms. Dagmar Rosa-Bjorkeson 44,326,023 11,344,296 2,680,975”
Xencor Inc reported first quarter ended March 31, 2023 results: revenue $19.0 million, net income Net loss for the first quarter ended March 31, 2023 was $60.8 million, EPS $(1.02) on a fully diluted per share basis.
“marketable debt securities totaled $568.2 million as of March 31, 2023, compared to $613.5 million on December 31, 2022. Revenues for the first quarter ended March 31, 2023 were $19.0 million, compared to $85.5 million for the same period in 2022. Total revenues earned in the first quarter of 2023 included milestone revenue earned from Xencor’s Janssen collaboration”
Allen Yang changed role as executive officer at Xencor Inc.
“Dr. Allen Yang will step down from his role as an executive officer of the Company. He will continue to be employed by the Company in a non-executive capacity.”
Nancy Valente was appointed as Executive Vice President and Chief Development Officer at Xencor Inc.
“Dr. Nancy Valente, age 64, was appointed as Executive Vice President and Chief Development Officer of the Company, effective May 1, 2023”
Nancy Valente resigned as Director at Xencor Inc.
“Dr. Nancy Valente tendered her offer of resignation from the Board of Directors (the "Board") of Xencor, Inc. (the "Company"), subject to the Board's acceptance of her resignation. Also on April 24, 2023, the Board accepted Dr. Valente's resignation, effective as of May 1, 2023.”
Xencor Inc entered into Sales Agreement with SVB Securities LLC valued at up to $200 million (effective 2023-02-27).
“On February 27, 2023, Xencor, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with SVB Securities LLC (the “Sales Agent”), pursuant to which the Company may issue and sell through the Sales Agent up to $200 million of shares of common stock”
Xencor Inc reported the fiscal year ended December 31, 2022 results: revenue $164.6 million.
“Revenues for the full year 2022 were $164.6 million compared to $275.1 million for the same period in 2021.”
Xencor Inc reported the fourth quarter ended December 31, 2022 results: revenue $21.6 million.
“Total revenue for the fourth quarter ended December 31, 2022 was $21.6 million compared to $154.0 million for the same period in 2021.”
Xencor Inc reported financial results for the quarter ended September 30, 2022.
“On November 7, 2022, Xencor, Inc. announced its financial results for the quarter ended September 30, 2022 in the press release attached hereto as Exhibit 99.1”
Nancy Valente was appointed as Director at Xencor Inc.
“On September 8, 2022, Nancy Valente was appointed to the Board of the Company.”
Yujiro S. Hata resigned as Director at Xencor Inc.
“On June 23, 2022, Yujiro S. Hata tendered his offer of resignation from the Board of Directors (the “Board”) of Xencor, Inc. (the “Company”), subject to the Board’s acceptance of his resignation. On September 8, 2022, the Board accepted Mr. Hata’s resignation.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.